The HPG-axis master regulator — acts upstream of LH and FSH to restore natural reproductive-hormone function, with emerging clinical data in fertility and libido research.
Kisspeptin-10 (KP-10) is the C-terminal decapeptide of the KISS1 gene product — a neuropeptide that acts as the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-producing neurons release it onto GnRH neurons; GnRH then triggers pituitary LH and FSH release, which drives testicular or ovarian function.
Pioneering clinical work at Imperial College London (Dhillo and colleagues) has demonstrated meaningful effects of kisspeptin on reproductive hormone release, sexual brain activity, and bonding — all without the HPG-suppression concern of direct TRT.
Not FDA approved. Not WADA prohibited. Actively studied in humans; research chemical for off-label use.
Binds KISS1R (also called GPR54) on GnRH neurons in the hypothalamus. GnRH is the master signal to the pituitary to release LH and FSH.
Because kisspeptin acts above GnRH, it triggers the entire cascade: GnRH → LH/FSH → testicular testosterone and spermatogenesis (or ovarian estradiol + follicular development). This is fundamentally different from TRT (which bypasses and suppresses the axis) or HCG (which stimulates testes directly).
Kisspeptin receptors are expressed in limbic regions, and Imperial College studies show kisspeptin enhances brain activity in sexual and bonding circuits in men — central effects beyond pure HPG activation. Note the detail this guide previously got wrong: those studies used intravenous kisspeptin-54. Intranasal delivery was only demonstrated in 2025 (Mills, PMID 40215751), also with kisspeptin-54, and for gonadotropin release rather than the brain-imaging endpoints.
| Benefit | Evidence |
|---|---|
| LH / testosterone pulse | This is the one benefit demonstrated with KP-10 itself in humans. George 2011 (PMID 21632807) gave healthy men IV bolus KP-10 across 0.01–3.0 mcg/kg: LH rose from 4.1 to 12.4 IU/L at 30 minutes, and a 22.5-hour infusion raised testosterone from 16.6 to 24.0 nmol/L (p < 0.001). Lower-rate infusion also increased LH pulse frequency |
| Fertility (IVF) | Real, and it is a hospital procedure rather than anything self-administered. In 261 women at high OHSS risk (Abbara 2018, PMID 29446481), the odds ratio for OHSS diagnosis was 33.6 (95% CI 12.6–89.5) after an hCG trigger versus a kisspeptin trigger, with median ovarian volume 138 mL after hCG vs 44 mL after kisspeptin. Retrospective and single-centre, and the Imperial trigger work used kisspeptin-54 |
| Libido / arousal (men) | Genuine trial evidence — for kisspeptin-54 given intravenously, not KP-10 and not intranasally. Comninos 2017 (PMID 28112678) found enhanced limbic activity to sexual and bonding stimuli in 29 men, correlating with reward and drive measures. Mills 2023 (PMID 36735255) went further: a placebo-controlled crossover RCT in 32 men with hypoactive sexual desire disorder, IV kisspeptin-54 at 1 nmol/kg/h, showing modulated sexual-processing brain activity and increased penile tumescence |
| Hypogonadotropic hypogonadism | Research suggests potential to restart HPG axis in functional hypothalamic cases |
| HPG axis recovery | Community interest as a PCT tool after anabolic cycles; clinical data limited |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThis distinction runs through everything below, and almost no vendor page makes it.
The KISS1 gene product is processed into several fragments. Kisspeptin-54 is the 54-amino-acid form; kisspeptin-10 is its C-terminal decapeptide and the minimal sequence retaining full intrinsic activity at KISS1R. They hit the same receptor, and they are not interchangeable in practice — KP-10 clears far faster, which is exactly why the Imperial group ran their longer protocols with KP-54.
| Finding | Which molecule |
|---|---|
| LH and testosterone rise in men | KP-10 (George 2011, PMID 21632807) |
| Sexual and emotional brain processing | KP-54, intravenous (PMIDs 28112678, 36735255) |
| IVF trigger with reduced OHSS | KP-54 (PMID 29446481) |
| Intranasal delivery | KP-54 (PMID 40215751) |
| Vascular and pro-atherosclerotic effects | KP-10 (PMID 32409274) |
The asymmetry is worth sitting with. Where KP-10 specifically has been studied, the strongest body of evidence is the vascular work — and it is a safety signal, not a benefit. The appealing findings people cite when buying KP-10 mostly belong to a different peptide, given intravenously in a hospital.
Not medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
This guide previously said once daily, optionally split AM/PM. That was wrong on the evidence, and frequency turns out to matter more than the number of micrograms — see below.
Clinical trials dosed by body weight, and the dose–response is not linear — it inverts. In George 2011 (PMID 21632807), LH release peaked at 1 mcg/kg, and 3 mcg/kg produced a smaller response than 1 mcg/kg (p < 0.05). For an 80 kg man, 1 mcg/kg is about 80 mcg — so the 100–300 mcg community range sits at or above the point where the response measurably fell off. The usual assumption that community doses are higher because peptide grade is unreliable does not rescue this: if anything, more of a correctly-made peptide performs worse here.
KISS1R tolerates repeated stimulation poorly, and the effect is fast. In women with hypothalamic amenorrhea given kisspeptin-54, twice-daily dosing produced complete tolerance — the LH response faded gradually and the FSH response was nearly abolished by day two. Switching to twice weekly produced only partial desensitisation, and those women still had significantly elevated reproductive hormones after eight weeks versus saline, with no adverse effects (Jayasena 2010, PMID 20980998).
That is the reason every-other-day or twice-weekly dosing is the sensible default, and why daily dosing is a poor idea even though it is widely suggested. It is also a neat pairing with the dose-response point above: with kisspeptin, pushing harder in either direction — more per dose, or more doses — tends to give you less.
Two honest caveats. This evidence is kisspeptin-54, not kisspeptin-10, and as the comparison section on this page explains, they are not interchangeable; it is the best available guide to frequency rather than a direct measurement of KP-10. And desensitisation is not universal — in healthy women with normal cycles, a week of twice-daily KP-54 did not abolish the acute LH response and cyclicity persisted (PMID 24030945). Profound tachyphylaxis is documented in male monkeys and in women with hypothalamic amenorrhea; a healthy axis appears more resilient. Nobody has measured this properly for subcutaneous KP-10 in men.
Kisspeptin stimulates your own testicular testosterone via the full HPG cascade. For men with a functional axis (primary or functional hypothalamic hypogonadism), this is ideal. For men with primary testicular failure, it won’t work — the testes themselves can’t respond.
It also will not do much alongside TRT. Kisspeptin works by stimulating GnRH neurons, and on exogenous testosterone those neurons are already silenced by negative feedback from testosterone and its estradiol metabolite. Adding a signal to a switch that has been turned off upstream is not a mechanism. If the goal is preserving testicular function on TRT, that is what hCG is used for — kisspeptin is the tool for an axis that is intact but underperforming, not a suppressed one.
Pre-filled with a typical Kisspeptin-10 setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Not medical advice. These figures describe what is reported in the literature and what practitioners and communities do — not a recommendation, and for most compounds here no human dose-finding study exists. Talk to a qualified healthcare provider.
5 mg vial + 2 mL BAC water = 2500 mcg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 100 mcg | 0.04 mL | 4 units |
| 200 mcg | 0.08 mL | 8 units |
| 300 mcg | 0.12 mL | 12 units |
Kisspeptin-10 is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
Lyvn does not carry Kisspeptin-10. They are the vendor we recommend elsewhere on this site, and they publish the full independent panel per batch — which makes their catalogue a useful yardstick for the criteria above even on a compound they do not stock. We are not recommending a specific supplier for Kisspeptin-10 itself, because we have no basis to.
For research use only. Not for human consumption. 21+.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeKisspeptin-10 (KP-10) is the C-terminal decapeptide of the KISS1 gene product. It is a neuropeptide that acts as the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons release it onto GnRH neurons, GnRH triggers pituitary LH and FSH release, and that drives testicular or ovarian function.
In men with a functional HPG axis, KP-10 reliably triggers an LH surge and downstream testosterone release. Because it acts upstream of GnRH, it stimulates the entire cascade rather than bypassing it. This is fundamentally different from TRT (which suppresses the axis) or hCG (which stimulates the testes directly), and is part of why kisspeptin has community interest as a PCT-style tool after anabolic cycles. Clinical data for that specific use is limited.
Not FDA approved and not WADA prohibited. It is actively studied in humans by groups like Imperial College London (Dhillo lab), but in the US it is sold as a research chemical for off-label use. A longer kisspeptin analog, kisspeptin-54, has been investigated as an IVF trigger in clinical trials and showed lower ovarian hyperstimulation syndrome risk than hCG trigger.
Community SubQ protocols run 100 to 300 mcg once daily, cycled 4 to 8 weeks on with 2 to 4 weeks off. Worth knowing that the human dose-response inverts: in George 2011 (PMID 21632807) LH release peaked at 1 mcg/kg and 3 mcg/kg gave a SMALLER response than 1 mcg/kg. For an 80 kg man 1 mcg/kg is about 80 mcg, so the common community range sits at or above the point where response fell off. A 5 mg vial in 2 mL BAC water yields 2500 mcg/mL, so 100 mcg is 4 units on an insulin syringe.
Common side effects are mild: injection site reactions, flushing, and transient headache. Important precautions: KISS1R is expressed across multiple tumor types and KP-10 is being investigated as a pan-tumor radiopharmaceutical target, so use caution with any active malignancy. Preclinical data also show KP-10 is a potent vasoconstrictor, induces endothelial senescence, and promotes pro-inflammatory gene expression, so use caution with cardiovascular or vascular disease.
Kisspeptin acts at the very top of the HPG axis (above GnRH), triggering the full cascade. hCG bypasses the axis and stimulates the testes directly, which is why it works even when upstream signaling is suppressed. Kisspeptin is also not a TRT replacement: it requires a functional axis, so men with primary testicular failure will not respond. Men already on TRT will not get override from kisspeptin because the axis is already suppressed; TRT must be discontinued first under medical guidance.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.